MY127670A - Pegylated interferon alfa-ccr5 antagonists combination hiv therapy - Google Patents
Pegylated interferon alfa-ccr5 antagonists combination hiv therapyInfo
- Publication number
- MY127670A MY127670A MYPI20001893A MYPI20001893A MY127670A MY 127670 A MY127670 A MY 127670A MY PI20001893 A MYPI20001893 A MY PI20001893A MY PI20001893 A MYPI20001893 A MY PI20001893A MY 127670 A MY127670 A MY 127670A
- Authority
- MY
- Malaysia
- Prior art keywords
- pegylated interferon
- interferon alfa
- hiv
- ccr5 antagonists
- hiv therapy
- Prior art date
Links
- 102000014150 Interferons Human genes 0.000 title 1
- 108010050904 Interferons Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 229940079322 interferon Drugs 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 3
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 208000003322 Coinfection Diseases 0.000 abstract 1
- 108010032976 Enfuvirtide Proteins 0.000 abstract 1
- 102000006992 Interferon-alpha Human genes 0.000 abstract 1
- 108010047761 Interferon-alpha Proteins 0.000 abstract 1
- 108010065805 Interleukin-12 Proteins 0.000 abstract 1
- 108010002350 Interleukin-2 Proteins 0.000 abstract 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 abstract 1
- 239000003067 chemokine receptor CCR5 antagonist Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000002651 drug therapy Methods 0.000 abstract 1
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 abstract 1
- 229960002062 enfuvirtide Drugs 0.000 abstract 1
- 229950000038 interferon alfa Drugs 0.000 abstract 1
- 229960000329 ribavirin Drugs 0.000 abstract 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30489799A | 1999-05-04 | 1999-05-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY127670A true MY127670A (en) | 2006-12-29 |
Family
ID=23178462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI20001893A MY127670A (en) | 1999-05-04 | 2000-05-02 | Pegylated interferon alfa-ccr5 antagonists combination hiv therapy |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1175224B1 (enExample) |
| JP (1) | JP2002543144A (enExample) |
| CN (1) | CN1349408A (enExample) |
| AR (1) | AR023824A1 (enExample) |
| AT (1) | ATE289516T1 (enExample) |
| AU (1) | AU776541B2 (enExample) |
| BR (1) | BR0010593A (enExample) |
| CA (1) | CA2365900A1 (enExample) |
| DE (1) | DE60018273T2 (enExample) |
| ES (1) | ES2238277T3 (enExample) |
| HK (1) | HK1039278B (enExample) |
| HU (1) | HUP0202734A3 (enExample) |
| MX (1) | MXPA01011116A (enExample) |
| MY (1) | MY127670A (enExample) |
| NO (1) | NO328679B1 (enExample) |
| NZ (1) | NZ514519A (enExample) |
| PE (1) | PE20010283A1 (enExample) |
| PT (1) | PT1175224E (enExample) |
| TW (1) | TWI289454B (enExample) |
| WO (1) | WO2000066141A2 (enExample) |
| ZA (1) | ZA200108870B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050065319A1 (en) * | 2000-12-19 | 2005-03-24 | Baroudy Bahige M. | Combination method for treating viral infections |
| CA2517888C (en) | 2003-03-14 | 2012-05-01 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient |
| EP2364982A1 (en) | 2003-04-18 | 2011-09-14 | ONO Pharmaceutical Co., Ltd. | Spiro-piperidine compounds as chemokine receptor antagonists and medicinal use thereof |
| EP1616862A4 (en) * | 2003-04-18 | 2008-07-16 | Ono Pharmaceutical Co | HETEROCYCLIC NITROGEN COMPOUND AND USE THEREOF |
| ES2294589T3 (es) | 2004-04-29 | 2008-04-01 | F. Hoffmann-La Roche Ag | Variacion de la secuencia nucleosida de ns5a como marcador. |
| PE20060598A1 (es) | 2004-09-13 | 2006-08-21 | Ono Pharmaceutical Co | Derivado heterociclo conteniendo nitrogeno como antagonista de quimiocina ccr5 |
| AU2006216731A1 (en) * | 2005-02-23 | 2006-08-31 | Schering Corporation | Piperidinyl piperazine derivatives useful as inhibitors of chemokine receptors |
| US20110052612A1 (en) | 2005-05-31 | 2011-03-03 | Ono Pharmaceutical Co., Ltd. | Spiropiperidine compound and medicinal use thereof |
| EP2657235A1 (en) | 2005-10-28 | 2013-10-30 | Ono Pharmaceutical Co., Ltd. | Compound containing basic group and use thereof |
| US8168783B2 (en) | 2005-11-18 | 2012-05-01 | Ono Pharmaceutical Co., Ltd. | Chemokine receptor antagonists and use thereof |
| KR20090008217A (ko) | 2006-03-10 | 2009-01-21 | 오노 야꾸힝 고교 가부시키가이샤 | 질소 함유 복소환 유도체 및 이들을 유효 성분으로 하는 약제 |
| WO2007132846A1 (ja) | 2006-05-16 | 2007-11-22 | Ono Pharmaceutical Co., Ltd. | 保護されていてもよい酸性基を含有する化合物およびその用途 |
| US20090325992A1 (en) | 2006-07-31 | 2009-12-31 | Ono Pharmaceutical Co., Ltd. | Compound having cyclic group bound thereto through spiro binding and use thereof |
| WO2010129351A1 (en) | 2009-04-28 | 2010-11-11 | Schepens Eye Research Institute | Method to identify and treat age-related macular degeneration |
| WO2013024022A1 (en) | 2011-08-12 | 2013-02-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
| AU2012338581B2 (en) | 2011-11-18 | 2016-12-08 | Nxera Pharma Uk Limited | Muscarinic M1 receptor agonists |
| SG11201605440TA (en) | 2014-01-08 | 2016-08-30 | Immunovative Therapies Ltd | Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome |
| GB201404922D0 (en) | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819961D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5889006A (en) * | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
| US5908621A (en) * | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| ES2214551T3 (es) * | 1995-11-02 | 2004-09-16 | Schering Corporation | Terapia de infusion continua de citocinas a baja dosis. |
| GB9609932D0 (en) * | 1996-05-13 | 1996-07-17 | Hoffmann La Roche | Use of IL-12 and IFN alpha for the treatment of infectious diseases |
| WO1998025617A1 (en) * | 1996-12-13 | 1998-06-18 | Merck & Co., Inc. | Substituted aryl piperazines as modulators of chemokine receptor activity |
| AR013669A1 (es) * | 1997-10-07 | 2001-01-10 | Smithkline Beecham Corp | Compuestos y metodos |
-
2000
- 2000-05-01 MX MXPA01011116A patent/MXPA01011116A/es active IP Right Grant
- 2000-05-01 PT PT00928604T patent/PT1175224E/pt unknown
- 2000-05-01 EP EP00928604A patent/EP1175224B1/en not_active Expired - Lifetime
- 2000-05-01 AT AT00928604T patent/ATE289516T1/de not_active IP Right Cessation
- 2000-05-01 AU AU46815/00A patent/AU776541B2/en not_active Ceased
- 2000-05-01 NZ NZ514519A patent/NZ514519A/en not_active IP Right Cessation
- 2000-05-01 HK HK02100826.8A patent/HK1039278B/en not_active IP Right Cessation
- 2000-05-01 CN CN00807116A patent/CN1349408A/zh active Pending
- 2000-05-01 BR BR0010593-7A patent/BR0010593A/pt not_active Application Discontinuation
- 2000-05-01 ES ES00928604T patent/ES2238277T3/es not_active Expired - Lifetime
- 2000-05-01 WO PCT/US2000/011634 patent/WO2000066141A2/en not_active Ceased
- 2000-05-01 CA CA002365900A patent/CA2365900A1/en not_active Abandoned
- 2000-05-01 DE DE60018273T patent/DE60018273T2/de not_active Expired - Lifetime
- 2000-05-01 JP JP2000615025A patent/JP2002543144A/ja not_active Ceased
- 2000-05-01 HU HU0202734A patent/HUP0202734A3/hu unknown
- 2000-05-02 PE PE2000000408A patent/PE20010283A1/es not_active Application Discontinuation
- 2000-05-02 MY MYPI20001893A patent/MY127670A/en unknown
- 2000-05-02 TW TW089108323A patent/TWI289454B/zh not_active IP Right Cessation
- 2000-05-02 AR ARP000102097A patent/AR023824A1/es unknown
-
2001
- 2001-10-26 ZA ZA200108870A patent/ZA200108870B/xx unknown
- 2001-11-02 NO NO20015367A patent/NO328679B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1175224B1 (en) | 2005-02-23 |
| JP2002543144A (ja) | 2002-12-17 |
| BR0010593A (pt) | 2002-02-13 |
| PT1175224E (pt) | 2005-07-29 |
| ES2238277T3 (es) | 2005-09-01 |
| AU776541B2 (en) | 2004-09-16 |
| HUP0202734A2 (hu) | 2002-12-28 |
| AR023824A1 (es) | 2002-09-04 |
| WO2000066141A3 (en) | 2001-02-08 |
| CA2365900A1 (en) | 2000-11-09 |
| TWI289454B (en) | 2007-11-11 |
| DE60018273D1 (de) | 2005-03-31 |
| DE60018273T2 (de) | 2005-08-18 |
| NO20015367L (no) | 2002-01-03 |
| ZA200108870B (en) | 2003-03-26 |
| NO328679B1 (no) | 2010-04-26 |
| NZ514519A (en) | 2003-07-25 |
| MXPA01011116A (es) | 2002-06-04 |
| HK1039278B (en) | 2005-06-30 |
| CN1349408A (zh) | 2002-05-15 |
| WO2000066141A2 (en) | 2000-11-09 |
| HK1039278A1 (en) | 2002-04-19 |
| PE20010283A1 (es) | 2001-03-16 |
| AU4681500A (en) | 2000-11-17 |
| HUP0202734A3 (en) | 2003-11-28 |
| EP1175224A2 (en) | 2002-01-30 |
| ATE289516T1 (de) | 2005-03-15 |
| NO20015367D0 (no) | 2001-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY127670A (en) | Pegylated interferon alfa-ccr5 antagonists combination hiv therapy | |
| ES2251196T3 (es) | Uso de peg-ifn-alfa y ribavirina para el tratamiento de hepatitis c cronica. | |
| US6007805A (en) | Use of interferon subtype alpha-8 (IFN-α8) to treat viral infections of the liver | |
| WO2000037110A3 (en) | Ribavirin-pegylated interferon alfa induction hcv combination therapy | |
| BR0114636A (pt) | Terapia combinada para hcv de interferon-alfa peguilado/ribavirina | |
| SG52443A1 (en) | Methods and compositions for the treatment of disease with interferon while reducing sid effects | |
| EA200200812A1 (ru) | Фармацевтическая композиция, содержащая низкую дозу энтекавира, и ее применение | |
| BR9712523A (pt) | Novos derivados de pirazol heterociclilmetil-substituìdos | |
| WO2002034284A3 (en) | Methods of therapy for hiv infection | |
| IL161889A (en) | Use of omega interferon in the manufacture of a medicament for treating viral disease | |
| PE20001386A1 (es) | Terapia de combinacion para el vhc por induccion de ribavirina-interferon alfa | |
| BR0108997A (pt) | Terapia imune adjuvante para hiv | |
| WO2000051631A3 (en) | Pegylated alpha interferon for hiv therapy | |
| ATE295729T1 (de) | Verwendung von einem mittel zur unterdrückung der infektion und der proliferation von hiv | |
| EP1023901A4 (en) | MEDICINES FOR HEPATITIS C AND THE USE THEREOF | |
| NZ514629A (en) | PEGylated interferon-alpha administered at about 4.5- 9.0 micrograms/kg/week as a renal cell carcinoma treatment | |
| AU2880595A (en) | Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses | |
| DK0862454T3 (da) | CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner | |
| WO2000043014A3 (en) | Beta-d-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine for use in the treatment of hiv infections | |
| James | Ribavirin approved for hepatitis C combination treatment | |
| WO1999038524A3 (en) | Therapeutic administration of low density lipoprotein receptor for viral infections and immune regulation | |
| MXPA03001145A (es) | Composicion farmaceutica para el tratamiento de la hepatitis c con timocina, interferon y ribavirin. | |
| CA2130988A1 (en) | Pharmaceutical Composition for Treatment of Sudden Deafness | |
| ECSP003462A (es) | Terapia de hiv de combinacion de antagonista ccr5 - interferon alfa pegilado (caso ino1024k) | |
| EP1731155A3 (en) | Beta-d-2', 3' -didehydro-2', 3' -dideoxy-5-fluorocytidine for use in the treatment of hiv infections |